PTJ
RCKT icon

Paul Tudor Jones’s Rocket Pharmaceuticals RCKT Stock Holding History

Paul Tudor Jones’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Hold
50,493
– – ﹤0.01% 3353
2026
Q1 		$181K Buy
50,493
+8,082
+19% +$32.1K ﹤0.01% 3394
2025
Q4 		$149K Sell
42,411
-7,696
-15% -$26.4K ﹤0.01% 3344
2025
Q3 		$163K Sell
50,107
-66
-0.1% -$208 ﹤0.01% 3228
2025
Q2 		$123K Buy
50,173
+36
+0.1% +$182 ﹤0.01% 3145
2025
Q1 		$334K Buy
50,137
+19,012
+61% +$188K ﹤0.01% 2526
2024
Q4 		$391K Buy
31,125
+14,338
+85% +$216K ﹤0.01% 2402
2024
Q3 		$310K Buy
+16,787
New +$344K ﹤0.01% 2302
2023
Q3 		– Sell
-22,873
Closed -$454K – 2765
2023
Q2 		$454K Buy
+22,873
New +$462K 0.01% 1766
2022
Q2 		– Sell
-32,787
Closed -$520K – 2448
2022
Q1 		$520K Buy
+32,787
New +$566K 0.01% 1256

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Paul Tudor Jones's RCKT Position: Q2 2026 in Review

Paul Tudor Jones held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 50,493 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #3353.

Paul Tudor Jones first reported a position in RCKT in Q1 2022 and has held it in 10 quarters since. The position peaked at $520K in Q1 2022. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Paul Tudor Jones held 50,493 shares of Rocket Pharmaceuticals worth $173K as of Q2 2026.
  • Paul Tudor Jones left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3353 holding.
  • Paul Tudor Jones first reported a position in Rocket Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
  • Paul Tudor Jones's Rocket Pharmaceuticals position peaked at $520K in Q1 2022.
  • 178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.